A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules
A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules
Progression
OTHER: Ablation therapy
progression free survival, One year progression free survival after radiofrequency ablation of ground glass nodules, 1 years
overall survival, overall survival after radiofrequency ablation of ground glass nodules, 1 years, 3 years, 5years
A prospective, two-center, single arm phase II clinical study to evaluate safety and effectiveness of ablation therapy in the treatment of lung cancer presenting as ground-glass nodules